<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01010841</url>
  </required_header>
  <id_info>
    <org_study_id>HMS4-MUL-CT</org_study_id>
    <nct_id>NCT01010841</nct_id>
  </id_info>
  <brief_title>Trial of Two Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome</brief_title>
  <acronym>HMS4</acronym>
  <official_title>Multi-center, Randomized Intervention to Compare the Effects of 2 Dietary Programs on Cardiometabolic Risk Factors in Subjects With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MetaProteomics LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MetaProteomics LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to investigate from 3 sites (University of Connecticut,
      University of Florida, and University of California, Irvine) whether enhancement of a
      modified Mediterranean-style, low glycemic load diet (MED) with specific phytochemicals (soy
      protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED) could improve
      cardiometabolic risk factors in women with metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As the worldwide dietary pattern becomes more westernized, the metabolic syndrome is reaching
      epidemic proportions. Lifestyle modifications including diet and exercise are recommended as
      first-line intervention for treating metabolic syndrome. Previously, we reported that
      specific phytochemical supplementation for 12 weeks (soy protein, phytosterols, rho iso-alpha
      acids and proanthocyanidins) increased the effectiveness of the modified Mediterranean-style
      low glycemic load dietary program on variables associated with metabolic syndrome and CVD in
      subjects with metabolic syndrome and elevated LDL cholesterol. In this study, we propose to
      conduct a multi-center randomized trial to confirm our previous findings.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TG-to-HDL ratio</measure>
    <time_frame>Baseline, 8 weeks, 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Components of metabolic syndrome (TG, HDL, resolution of MetS)</measure>
    <time_frame>Baseline, 8 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose intolerance (fasting glucose/insulin, leptin, HbA1c, HOMA score)</measure>
    <time_frame>Baseline, 8 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CVD risk factors (cholesterol, LDL, chol/HDL, apoAI, apoB, apoAII, apoCII, apoCIII, apoE, homocysteine, RBC fatty acids, Framingham risk score)</measure>
    <time_frame>Baseline, 8 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory cytokines (TNF-alpha, IL-6, sICAM, sVCAM, MCP1)</measure>
    <time_frame>Baseline, 8 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition (weight, BMI, % body fat, % lean mass, waist-to-hip ratio, DEXA scanning)</measure>
    <time_frame>Baseline, 8 weeks, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective assessment (MOS-MCS/PCS questionnaires, VAS-satiety/craving questionnaires)</measure>
    <time_frame>baseline, then every 2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">89</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Overweight</condition>
  <condition>Obesity</condition>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Low-glycemic-load diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Modified Mediterranean-style low-glycemic-load diet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-glycemic-load diet + medical food</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified Mediterranean-style, low-glycemic-load diet + medical food</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>UltraMealPlus 360 (Medical food)</intervention_name>
    <description>Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)</description>
    <arm_group_label>Low-glycemic-load diet + medical food</arm_group_label>
    <other_name>UltraMealPlus 360</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Low-glycemic-load diet</intervention_name>
    <description>Modified Mediterranean-style low-glycemic-load diet</description>
    <arm_group_label>Low-glycemic-load diet</arm_group_label>
    <arm_group_label>Low-glycemic-load diet + medical food</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI ≥25 and &lt;45

          -  LDL &gt;100 mg/dl

          -  TG ≥150 and &lt;400 mg/dl

          -  meet 2 or more of the following 4 criteria:

               -  HDL &lt;50 mg/dl

               -  blood pressure ≥130/85 mmHg (or diagnosed hypertension on medication)

               -  fasting glucose ≥100 mg/dl and &lt;150 mg/dl

               -  waist circumference &gt;35 inches

        Exclusion Criteria:

          -  Medical History and Concurrent Diseases

               1. Over the preceding 4 weeks, initiation or cessation of regular exercise

               2. Over the preceding 4 weeks, involvement in a significant diet or weight loss
                  program such as Atkin's diet program, a very low calorie liquid program (such as
                  Optifast, Medifast, and HMR), or any diet that has led to a weight loss of 10% of
                  body weight over a period of 6 weeks

               3. Use of blood sugar lowering medications including thiazolidinedione class of oral
                  medications including Avandia (rosiglitazone), Avandamet
                  (metformin/rosiglitazone), Actos (pioglitazone), metformin (Glucophage, Fortamet,
                  Riomet) or insulin over the preceding 12 weeks

               4. Over the preceding 4 weeks, regular use of Kaprex® or Kaprex AI® at least 3
                  days/week

               5. Over the preceding 4 weeks, regular use of NSAIDs (i.e. ibuprofen, celecoxib,
                  etc.) at least 3 days per week

               6. Over the preceding 12 weeks, use of cholesterol lowering medications, either by
                  prescription (statins, etc.) or over-the-counter (gugulipids, niacin, etc.)

               7. Over the preceding 12 weeks, use of oral or injectable corticosteroids, such as
                  prednisone

               8. Current use of oral anticoagulants such as Coumadin or injectable anticoagulants
                  such as Heparin or Low Molecular Weight Heparin

               9. Use of electronic implants such as pacemakers, defibrillators, nerve stimulators

              10. Allergy to one or more of the ingredients in the investigational products

              11. Poorly controlled hypertension (blood pressure above 155/95)

              12. History of significant liver or kidney disease (recent or ongoing hepatitis,
                  cirrhosis, glomerulonephritis, dialysis treatment, etc.)

              13. History of serious heart disease (heart attack, angina, cardiac surgery,
                  arrhythmia, or congestive heart failure)

              14. History of deep vein thrombosis or pulmonary embolus (blood clot to lungs)

              15. History of autoimmune diseases such as inflammatory bowel disease (Crohn's
                  disease, and/or ulcerative colitis), multiple sclerosis, rheumatoid arthritis,
                  systemic lupus erythematosus, polymyositis, scleroderma and thyroiditis

              16. History of eating disorder (anorexia nervosa or bulimia) in preceding 5 years

              17. History of alcoholism or drug addiction in the preceding 5 years

              18. History of serious mental illness

              19. History of attempted suicide in past 10 years

              20. Untreated endocrine, neurological, or infectious disorder

              21. Diagnosis of Human Immunodeficiency Virus (HIV) or Acquired HIV (AIDS)

              22. Current cancer or a history of cancer (except skin cancer)

              23. Pregnancy or lactation

              24. If female of childbearing potential, unwillingness to practice a reliable method
                  of birth control (i.e. physical sperm barriers or hormonal therapies)

              25. Any other sound medical, psychiatric and/or social reason as determined by the
                  Principal Investigator (PI).

          -  Physical and Laboratory Test Findings

               1. TG ≥ 400 mg/dl

               2. abnormal blood count (Hct &lt; 30 or &gt; 47%, WBC &lt; 3,000 or &gt; 12,000, platelets &lt;140
                  or &gt; 500)

               3. abnormal kidney function test(s) (BUN &gt; 30 mg/dL or creatinine &gt; 1.5 mg/dL) or
                  liver function test(s) (bilirubin total &gt; 2.0 mg/dL, ALT &gt; 75 IU/L, AST &gt; 75
                  IU/L; Alk Phos &gt; 130 IU)

               4. fasting glucose &gt;150 mg/dL, serum calcium (&gt;10.5 mg/dL), positive pregnancy test
                  (ß-hCG in blood)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert H Lerman, MD/PhD</last_name>
    <role>Study Director</role>
    <affiliation>MetaProteomics LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark McIntosh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Luz Fernandez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Connecticut</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wadie Najm, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California at Irvine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mark McIntosh MD</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jones JL, Fernandez ML, McIntosh MS, Najm W, Calle MC, Kalynych C, Vukich C, Barona J, Ackermann D, Kim JE, Kumar V, Lott M, Volek JS, Lerman RH. A Mediterranean-style low-glycemic-load diet improves variables of metabolic syndrome in women, and addition of a phytochemical-rich medical food enhances benefits on lipoprotein metabolism. J Clin Lipidol. 2011 May-Jun;5(3):188-96. doi: 10.1016/j.jacl.2011.03.002. Epub 2011 Mar 11.</citation>
    <PMID>21600524</PMID>
  </results_reference>
  <results_reference>
    <citation>Fernandez ML, Jones JJ, Ackerman D, Barona J, Calle M, Comperatore MV, Kim JE, Andersen C, Leite JO, Volek JS, McIntosh M, Kalynych C, Najm W, Lerman RH. Low HDL cholesterol is associated with increased atherogenic lipoproteins and insulin resistance in women classified with metabolic syndrome. Nutr Res Pract. 2010 Dec;4(6):492-8. doi: 10.4162/nrp.2010.4.6.492. Epub 2010 Dec 28.</citation>
    <PMID>21286407</PMID>
  </results_reference>
  <results_reference>
    <citation>Ackermann D, Jones J, Barona J, Calle MC, Kim JE, LaPia B, Volek JS, McIntosh M, Kalynych C, Najm W, Lerman RH, Fernandez ML. Waist circumference is positively correlated with markers of inflammation and negatively with adiponectin in women with metabolic syndrome. Nutr Res. 2011 Mar;31(3):197-204. doi: 10.1016/j.nutres.2011.02.004.</citation>
    <PMID>21481713</PMID>
  </results_reference>
  <results_reference>
    <citation>Barona J, Jones JJ, Kopec RE, Comperatore M, Andersen C, Schwartz SJ, Lerman RH, Fernandez ML. A Mediterranean-style low-glycemic-load diet increases plasma carotenoids and decreases LDL oxidation in women with metabolic syndrome. J Nutr Biochem. 2012 Jun;23(6):609-15. doi: 10.1016/j.jnutbio.2011.02.016. Epub 2011 Jul 19.</citation>
    <PMID>21775117</PMID>
  </results_reference>
  <results_reference>
    <citation>Jones JL, Comperatore M, Barona J, Calle MC, Andersen C, McIntosh M, Najm W, Lerman RH, Fernandez ML. A Mediterranean-style, low-glycemic-load diet decreases atherogenic lipoproteins and reduces lipoprotein (a) and oxidized low-density lipoprotein in women with metabolic syndrome. Metabolism. 2012 Mar;61(3):366-72. doi: 10.1016/j.metabol.2011.07.013. Epub 2011 Sep 23.</citation>
    <PMID>21944261</PMID>
  </results_reference>
  <results_reference>
    <citation>Jones JL, Park Y, Lee J, Lerman RH, Fernandez ML. A Mediterranean-style, low-glycemic-load diet reduces the expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in mononuclear cells and plasma insulin in women with metabolic syndrome. Nutr Res. 2011 Sep;31(9):659-64. doi: 10.1016/j.nutres.2011.08.011.</citation>
    <PMID>22024489</PMID>
  </results_reference>
  <results_reference>
    <citation>Jones JL, Ackermann D, Barona J, Calle M, Andersen C, Kim JE, Volek JS, McIntosh M, Najm W, Lerman RH, Fernandez ML. A Mediterranean low-glycemic-load diet alone or in combination with a medical food improves insulin sensitivity and reduces inflammation in women with metabolic syndrome. British Journal of Medicine &amp; Medical Research 1(4):356-370, 2011.</citation>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2009</study_first_submitted>
  <study_first_submitted_qc>November 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2009</study_first_posted>
  <last_update_submitted>January 11, 2012</last_update_submitted>
  <last_update_submitted_qc>January 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Serum lipid</keyword>
  <keyword>Dietary intervention</keyword>
  <keyword>Lifestyle modification</keyword>
  <keyword>Glycemic load</keyword>
  <keyword>Phytochemical</keyword>
  <keyword>Hops</keyword>
  <keyword>Acacia</keyword>
  <keyword>Mediterranean diet</keyword>
  <keyword>Kinase modulator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

